Capricor gets up to $735M for Duchenne drug's US rights; PCI Biotech ends bile duct cancer clinical trial
Capricor Therapeutics is still chugging along.
The San Diego biotech signed a new collaboration with Japanese pharma company Nippon Shinyaku, whose US subsidiary is NS Pharma. Capricor earns a $30 million upfront payment to run its Phase III trial for its lead Duchenne cell therapy program while leaving the door open for $705 million in potential milestones.
Nippon Shinyaku, meanwhile, gets US distribution rights and will be in charge of such efforts. Capricor will run the pivotal study and handle manufacturing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.